Catheter Precision (NYSE:VTAK) shares are down on Thursday as the company announced a strategic divestiture of its non-core assets.VTAK Sells Atherectomy Catheter Tech to Focus on ElectrophysiologyCatheter Precision on Thursday agreed to sell its atherectomy catheter technologies, including associated FDA approvals and patents, to a strategic acquirer.This decision aims to enhance capital efficiency and sharpen the company’s focus on its high-growth electrophysiology platform.The divestiture is expected to ...